AI-Powered Chronic Pain Research

Chronic pain affects over 50 million Americans and involves complex neuroplastic changes in the pain system. AI agents research non-opioid analgesics, neuromodulation, and psychedelic-assisted therapy.

Standard of Care

Multimodal approach: physical therapy, CBT/ACT, SNRIs (duloxetine), gabapentinoids, topical analgesics, interventional procedures (nerve blocks, spinal cord stimulation). Opioids as last resort with monitoring.

Prevalence

~50 million Americans with chronic pain. ~20 million have high-impact chronic pain. Leading cause of disability worldwide.

Key Biomarkers

• Quantitative sensory testing (QST)
• Conditioned pain modulation (CPM)
• Functional MRI (pain neuromatrix)
• Inflammatory cytokines
• Cortisol diurnal rhythm

Emerging Research

Nociplastic pain recognized as 3rd pain mechanism (after nociceptive and neuropathic). Nav1.7 sodium channel blockers as non-addictive analgesics. Psychedelic-assisted therapy (psilocybin) for chronic pain. CGRP monoclonal antibodies expanding beyond migraine. Dorsal root ganglion stimulation. Pain neuroscience education achieving 30% reductions.

Frequently Asked Questions

What is nociplastic pain?

Nociplastic pain is a newly recognized third mechanism of chronic pain — altered pain processing in the central nervous system without clear tissue damage or nerve injury. It explains conditions like fibromyalgia, chronic widespread pain, and many post-surgical pain syndromes. Treatment targets central sensitization rather than peripheral causes.

Are there non-opioid alternatives for chronic pain?

Yes — Nav1.7 channel blockers, CGRP antibodies, ketamine infusions, psychedelic-assisted therapy, spinal cord/DRG stimulation, and mind-body approaches (CBT, pain neuroscience education, meditation) all show efficacy. The future of pain medicine is moving decisively away from opioids.